Allotransplantation

TheraCell Announces Immediate Release Of Its TheraFuze DBF® Fiber Bag Solution For Graft Containment In Spinal Surgery

Tuesday, March 2, 2021 - 7:27pm

LOS ANGELES, March 2, 2021 /PRNewswire/ -- TheraCell Inc., a leading allograft solution company, today announced thatits newest procedure-specific fiber graft form, the TheraFuze DBF Fiber Bag, is now available for use in spinal and orthopedic surgeries, including minimally invasive procedures.

Key Points: 
  • LOS ANGELES, March 2, 2021 /PRNewswire/ -- TheraCell Inc., a leading allograft solution company, today announced thatits newest procedure-specific fiber graft form, the TheraFuze DBF Fiber Bag, is now available for use in spinal and orthopedic surgeries, including minimally invasive procedures.
  • The TheraFuze DBF Fiber Bag is a 100% allograft tissue alternative to the resorbable polymer mesh bag products that are currently on the market.
  • The Fiber Bag is made from cortical demineralized bone fibers and processed using TheraCell's proprietary Bone Textile technology.
  • TheraFuze DBF, TheraFuze DBF Fiber Bag, TheraFuze DBF FiberLok, Bone Textile and The Bag That Is A Graft are trademarks of TheraCell, Inc.
    For more information on these products, please visit TheraCell's website .

AlloSource Announces First Patients Implanted With AlloWrap Amniotic Membrane In Clinical Study For Two-Level Anterior Cervical Discectomy And Fusion Procedures

Tuesday, February 23, 2021 - 6:40pm

The primary objective of this study is to obtain evidence of the effectiveness of AlloWrap Amniotic Membrane in the reduction of soft tissue swelling in two-level ACDF procedures.

Key Points: 
  • The primary objective of this study is to obtain evidence of the effectiveness of AlloWrap Amniotic Membrane in the reduction of soft tissue swelling in two-level ACDF procedures.
  • "Though I have performed many successful anterior cervical discectomy and fusion procedures, I am always looking for ways to improve patient outcomes," said Dr. Paul Kim with The Spine Institute of San Diego.
  • AlloSource's AlloWrap is a human amniotic membrane designed to provide a biologic barrier following surgical repair in a multitude of procedures.
  • Founded in 1994, AlloSource is a nonprofit leader in providing allografts that maximize tissue donation to help surgeons heal their patients.

Kolosis BIO and MTF Biologics Announce Launch of Kore Fiber™

Wednesday, February 17, 2021 - 9:00pm

Kolosis BIO, LLC (Kolosis) announced today, in collaboration with MTF Biologics (MTF), the market release of Kore Fiber, an exclusively processed demineralized cortical fiber allograft for Kolosis.

Key Points: 
  • Kolosis BIO, LLC (Kolosis) announced today, in collaboration with MTF Biologics (MTF), the market release of Kore Fiber, an exclusively processed demineralized cortical fiber allograft for Kolosis.
  • Kolosis Chief Executive Officer Collin Begley noted, "We are extremely excited to launch Kore Fiber with MTF Biologics.
  • We could not be more excited to add Kore Fiber to our exclusive MTF portfolio of bone graft tissues.
  • The addition of Kore Fiber further establishes Kolosis as a notable player in the orthobiologics space.

Akan Biosciences Announces FDA Acceptance of IND Application for StroMel™ in Osteoarthritis of Knee

Tuesday, February 16, 2021 - 11:27am

Although the current IND is for autologous administration, Akan is planning to explore allogeneic applications as well.

Key Points: 
  • Although the current IND is for autologous administration, Akan is planning to explore allogeneic applications as well.
  • The President of Akan, Dr. Mukesh Kumar, is a veteran of FDA regulated products having taken hundreds of products through FDA.
  • ABOUT THE COMPANY: Akan Biosciences, LLC (Akan), aMaryland based, clinical stage biotech company innovating cellular technology and proprietary manufacturing methods to produce stem cell-based therapeutics.
  • Akan is part of the Maryland Tech Council and Biohealth Innovation, Inc..
    View original content to download multimedia: http://www.prnewswire.com/news-releases/akan-biosciences-announces-fda-a...

Asia Pacific Bone Grafts & Substitutes Market Size, Share & Trends Analysis Report 2020 - 2027 - ResearchAndMarkets.com

Monday, February 15, 2021 - 1:02pm

The "Asia Pacific Bone Grafts & Substitutes Market Size, Share & Trends Analysis Report by Product (Allograft, Synthetic), by Application (Spinal Fusion, Dental, Craniomaxillofacial, Foot & Ankle, Joint Reconstruction, Long Bone), and Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia Pacific Bone Grafts & Substitutes Market Size, Share & Trends Analysis Report by Product (Allograft, Synthetic), by Application (Spinal Fusion, Dental, Craniomaxillofacial, Foot & Ankle, Joint Reconstruction, Long Bone), and Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Asia Pacific bone grafts and substitutes market size is expected to reach USD 922.4 million by 2027, expanding at a CAGR of 7.1%.
  • Increasing demand for the development of biocompatible bone grafts in order to reduce adverse reaction is driving demand for synthetic grafts.
  • Chapter 3 Asia Pacific Bone grafts & substitutes Market Variables, Trends & Scope

MiMedx to Participate at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Wednesday, February 10, 2021 - 1:00pm

A live webcast of the presentation will be available on the Events page of the Investors section of the Companys website or through the conference site by using the link below.

Key Points: 
  • A live webcast of the presentation will be available on the Events page of the Investors section of the Companys website or through the conference site by using the link below.
  • A replay of the webcast will be available for approximately 90 days on the Companys website at www.mimedx.com following the conclusion of the presentation.
  • The Company processes the human placental tissue utilizing its proprietary PURIONprocess methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization.
  • MiMedx has supplied more than two million allografts, through both direct and consignment shipments.

Increased Prevalence of Lifestyle Diseases and Technological Progress in Dental Implants to Drive Growth of the Global Soft Tissue Allografts Market: TMR

Tuesday, February 9, 2021 - 3:30pm

This factor is likely to support growth of the global soft tissue allografts market over the analysis timeline, from 2019 to 2027.

Key Points: 
  • This factor is likely to support growth of the global soft tissue allografts market over the analysis timeline, from 2019 to 2027.
  • The global soft tissue allografts market is expected to register a growth rate of ~6.5% over the forecast timeline, from 2019 to 2027.
  • These factors are likely to foster growth of the global soft tissue allografts market in the near future.
  • Increased prevalence of such health conditions is likely to foster expansion of the global soft tissue allografts market in the forthcoming years.

Increased Prevalence of Lifestyle Diseases and Technological Progress in Dental Implants to Drive Growth of the Global Soft Tissue Allografts Market: TMR

Tuesday, February 9, 2021 - 3:30pm

- Increased prevalence of anterior cruciate ligament injuries and presence of technologically advanced research platforms to work in favor of the global soft tissue allografts market.

Key Points: 
  • - Increased prevalence of anterior cruciate ligament injuries and presence of technologically advanced research platforms to work in favor of the global soft tissue allografts market.
  • This factor is likely to support growth of the global soft tissue allografts market over the analysis timeline, from 2019 to 2027.
  • The global soft tissue allografts market is expected to register a growth rate of ~6.5% over the forecast timeline, from 2019 to 2027.
  • Increased prevalence of such health conditions is likely to foster expansion of the global soft tissue allografts market in the forthcoming years.

CareDx Showcases Cellular Transplantation and Therapy Portfolio at TCT

Friday, February 5, 2021 - 12:00pm

Quantification of Chimerism and Graft Immune Cell Composition with AlloSeq HCT, a Wide Range Next-Generation Sequencing Assay with High Sensitivity, Accuracy and Precision for Routine Monitoring in Patients Post-Hematopoietic Stem Cell Transplantation

Key Points: 
  • Quantification of Chimerism and Graft Immune Cell Composition with AlloSeq HCT, a Wide Range Next-Generation Sequencing Assay with High Sensitivity, Accuracy and Precision for Routine Monitoring in Patients Post-Hematopoietic Stem Cell Transplantation
    TCT will highlight CareDxs growth in cellular transplantation and therapy, and showcase our suite of solutions including AlloCell, AlloHeme, AlloSeq HCT, and Ottr Cellular.
  • I am particularly excited to share this early data on AlloCells value in Ataras clinical trial as we further the science of allogeneic CAR-T therapy, said, Sham Dholakia, MD, Senior Vice President, Medical Affairs & Clinical Operations, CareDx.
  • Atara Biotherapeutics is excited to partner with CareDx to pioneer a novel NGS solution for advancing allogeneic cell therapies.
  • The data being presented atTCT2021 is a testament to both CareDx and Ataras focus on bringing transformative cell therapies to patients around the world, said Jakob Dupont, M.D., Executive Vice President and Global Head of Research and Development, Atara Biotherapeutics.

AlloSource's ProChondrix CR, Cryopreserved Osteochondral Allograft, To Be Featured At The British Patellofemoral Society Meeting

Friday, January 15, 2021 - 6:04pm

During the session titled ProChondrix CR: Cryopreserved off-the-shelf Hyaline Cartilage Allograft.

Key Points: 
  • During the session titled ProChondrix CR: Cryopreserved off-the-shelf Hyaline Cartilage Allograft.
  • Dr. Argo, with Beacon Orthopaedics and Sports Medicine in Cincinnati, Ohio, will highlight his experience repairing osteochondral defects of the knee with AlloSource's allograft.
  • A potentially debilitating condition, chondral injuries are a common issue that affect nearly one million people in the United States annually.
  • "This meeting provides a great opportunity to share my experience with ProChondrix for cartilage defects in the knee," said Dr. Argo.